在非小细胞肺癌中BRAF突变的多样性以及对治疗的影响
Kevin Lu1, John Paul Shen2, Fernando J Lopez-Diaz3
1UC San Diego, La Jolla, CA, USA.
NPJ precision oncology
|October 29, 2025
概括
在非小细胞肺癌 (NSCLC) 中,BRAF-MEK 抑制剂提高了具有I类BRAF突变的存活率. 非典型的BRAF变体表现出不同的依赖性,需要为NSCLC患者量身定制的治疗策略.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于具有BRAF突变的非小细胞肺癌 (NSCLC) 的最佳治疗顺序尚未确定.
- 在NSCLC中BRAF突变可以分为I,II和III类,具有不同的临床影响.
- 非典型的BRAF变体在治疗决策中提出了独特的挑战.
研究的目的:
- 研究BRAF-MEK抑制剂和免疫检查点抑制剂在患有BRAF突变的NSCLC患者中的疗效.
- 描述NSCLC中不同BRAF突变类的基因组景观和药物依赖性.
- 为了解决BRAF突变NSCLC的最佳治疗策略.
主要方法:
- 对BRAF突变NSCLC患者的多机构队列 (n=97) 和独立的临床基因组数据库 (n=342) 的回顾性分析.
- 对BRAF突变NSCLC细胞系的结构建模和化学选.
- 基于治疗方案 (BRAF-MEK 抑制剂,免疫检查点抑制剂) 的比较生存分析.
主要成果:
- 接受BRAF-MEK抑制剂的I类BRAF突变患者的整体存活率显著改善 (40个月与10个月相比).
- 与免疫检查点抑制剂没有观察到显著的生存差异.
- 二/三类BRAF变异更有可能同时发生MAPK路径改变;二类细胞依赖BRAF而不是抑制剂,而三类细胞依赖EGFR.
结论:
- BRAF-MEK 抑制剂对于患有 I 类 BRAF 突变的 NSCLC 患者来说是一个可行的治疗选择.
- 非典型的BRAF变种 (II/III类) 呈现出明显的遗传依赖性,表明需要替代性或组合疗法.
- 对BRAF突变NSCLC的治疗策略应根据特定的BRAF突变类和相关的基因组变化量身定制.
更多相关视频
相关概念视频
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
The Retinoblastoma Gene
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.7K


